Kenvue Inc.
At today's price, Kenvue Inc. (KVUE) is priced for -2.8% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
• Kenvue is the world's largest pure-play consumer health company, with $15.5 billion in fiscal 2024 net sales across Self Care, Skin Health and Beauty, and Essential Health, home to Tylenol, Neutrogena, Listerine, and Band-Aid [Source: Kenvue FY2024 10-K]. • The defining fact is a pending takeover: Kimberly-Clark has agreed to acquire Kenvue, shareholders have approved, and the deal is expected to close in the second half of 2026, so the stock now trades largely on deal completion rather than s
Is KVUE overvalued? See what's priced in →
986 institutional managers reported holding KVUE in 13F filings for the quarter ended 2026-03-31. Together they hold about 90% of the company; the top 10 hold 47%. 105 opened new positions that quarter. Held by Vanguard Group, BlackRock, FMR (Fidelity), among others. On the short side, 68.6M shares were sold short as of the 2026-06-15 count, about 4% of shares outstanding (3.5 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
KVUE's share count grew 11.8% over the past five years even with $439.00M spent on repurchases. It pays a dividend, and has paid one every year in our records (3 and counting), raised 2 years straight; the current rate is $0.82 a share annually. Cash returned over the past three years: $4.30B in dividends and $439.00M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at KVUE over the trailing three years: 2023: 1 buy totaling $129k; 2025: 2 buys totaling $110.97M. 15 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
KVUE's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-03 | -4.0% | -17.6% |
| 2023-11-04 | -7.7% | +10.2% |
| 2024-03-02 | -5.8% | +2.0% |
| 2024-05-10 | +7.2% | -10.7% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
KVUE's latest 8-K filings: 2026-05-22 (items 5.07); 2026-05-07 (items 2.02, 9.01); 2026-04-15 (items 5.02, 9.01); 2026-02-17 (items 2.02, 2.05, 9.01); 2026-02-12 (items 5.02).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.